- Home
- EYPT vs URGN Comparison
EYPT vs URGN Comparison
Compare EYPT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- URGN
- Stock Information
- Founded
- EYPT 1987
- URGN 2004
- Country
- EYPT United States
- URGN United States
- Employees
- EYPT N/A
- URGN N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- URGN Health Care
- Exchange
- EYPT Nasdaq
- URGN Nasdaq
- Market Cap
- EYPT 427.9M
- URGN 465.9M
- IPO Year
- EYPT 2005
- URGN 2017
- Fundamental
- Price
- EYPT $6.51
- URGN $10.05
- Analyst Decision
- EYPT Strong Buy
- URGN Strong Buy
- Analyst Count
- EYPT 8
- URGN 7
- Target Price
- EYPT $25.71
- URGN $37.21
- AVG Volume (30 Days)
- EYPT 841.5K
- URGN 487.2K
- Earning Date
- EYPT 05-07-2025
- URGN 05-12-2025
- Dividend Yield
- EYPT N/A
- URGN N/A
- EPS Growth
- EYPT N/A
- URGN N/A
- EPS
- EYPT N/A
- URGN N/A
- Revenue
- EYPT $43,273,000.00
- URGN $90,398,000.00
- Revenue This Year
- EYPT N/A
- URGN $38.65
- Revenue Next Year
- EYPT N/A
- URGN $118.69
- P/E Ratio
- EYPT N/A
- URGN N/A
- Revenue Growth
- EYPT N/A
- URGN 9.29
- 52 Week Low
- EYPT $3.91
- URGN $8.94
- 52 Week High
- EYPT $21.26
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- EYPT 61.19
- URGN 45.94
- Support Level
- EYPT $5.37
- URGN $9.36
- Resistance Level
- EYPT $5.86
- URGN $10.83
- Average True Range (ATR)
- EYPT 0.57
- URGN 0.78
- MACD
- EYPT 0.20
- URGN -0.06
- Stochastic Oscillator
- EYPT 99.81
- URGN 45.12
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.